journal

Journal of Clinical Oncology

journal
https://read.qxmd.com/read/31697589/reply-to-farolfi-et-al-and-haines-et-al
#1
Krishnansu S Tewari, Bradley J Monk, Robert A Burger
No abstract text is available yet for this article.
November 7, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31697588/bevacizumab-moonshots-an-important-outcome-from-the-latest-ovarian-cancer-mission
#2
LETTER
Ian Edwin Haines, George L Gabor Miklos
No abstract text is available yet for this article.
November 7, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31697587/bevacizumab-as-maintenance-treatment-in-patients-with-ovarian-cancer-wait-for-brca-testing
#3
LETTER
Alberto Farolfi, Domenica Lorusso, Sandro Pignata, Ugo De Giorgi
No abstract text is available yet for this article.
November 7, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31693429/polatuzumab-vedotin-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma
#4
Laurie H Sehn, Alex F Herrera, Christopher R Flowers, Manali K Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhit Ozcan, Jamie Hirata, Elicia Penuel, Joseph N Paulson, Ji Cheng, Grace Ku, Matthew J Matasar
PURPOSE: Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options. The antibody-drug conjugate polatuzumab vedotin targets CD79b, a B-cell receptor component. METHODS: Safety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) was evaluated in a single-arm cohort. Polatuzumab vedotin combined with bendamustine and rituximab (pola-BR) was compared with bendamustine and rituximab (BR) in a randomly assigned cohort of patients with transplantation-ineligible R/R DLBCL (primary end point: independent review committee [IRC] assessed complete response [CR] rate at the end of treatment)...
November 6, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31689155/phase-i-study-of-dstp3086s-an-antibody-drug-conjugate-targeting-six-transmembrane-epithelial-antigen-of-prostate-1-in-metastatic-castration-resistant-prostate-cancer
#5
Daniel C Danila, Russell Z Szmulewitz, Ulka Vaishampayan, Celestia S Higano, Ari D Baron, Houston N Gilbert, Flavia Brunstein, Marija Milojic-Blair, Bei Wang, Omar Kabbarah, Michael Mamounas, Bernard M Fine, Daniel J Maslyar, Alexander Ungewickell, Howard I Scher
PURPOSE: Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is highly expressed in prostate cancers. DSTP3086S is a humanized immunoglobulin G1 anti-STEAP1 monoclonal antibody linked to the potent antimitotic agent monomethyl auristatin E. This study evaluated the safety and activity of DSTP3086S in patients with metastatic castration-resistant prostate cancer. METHODS: Patients were enrolled in a 3 + 3 dose escalation study to evaluate DSTP3086S (0...
November 5, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31682550/efficacy-of-pembrolizumab-in-patients-with-noncolorectal-high-microsatellite-instability-mismatch-repair-deficient-cancer-results-from-the-phase-ii-keynote-158-study
#6
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen, Sarina A Piha-Paul, Toshihiko Doi, Bo Gao, Hyun Cheol Chung, Jose Lopez-Martin, Yung-Jue Bang, Ronnie Shapira Frommer, Manisha Shah, Razi Ghori, Andrew K Joe, Scott K Pruitt, Luis A Diaz
PURPOSE: Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations that encode potential neoantigens. Such tumors are therefore likely to be immunogenic, triggering upregulation of immune checkpoint proteins. Pembrolizumab, an anti‒programmed death-1 monoclonal antibody, has antitumor activity against MSI-H/dMMR cancer. We report data from the phase II KEYNOTE-158 study of pembrolizumab in patients with previously treated, advanced noncolorectal MSI-H/dMMR cancer...
November 4, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31682542/gefitinib-alone-versus-gefitinib-plus-chemotherapy-for-non-small-cell-lung-cancer-with-mutated-epidermal-growth-factor-receptor-nej009-study
#7
Yukio Hosomi, Satoshi Morita, Shunichi Sugawara, Terufumi Kato, Tatsuro Fukuhara, Akihiko Gemma, Kazuhisa Takahashi, Yuka Fujita, Toshiyuki Harada, Koichi Minato, Kei Takamura, Koichi Hagiwara, Kunihiko Kobayashi, Toshihiro Nukiwa, Akira Inoue
PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic chemotherapy is highly effective for the treatment of advanced non-small-cell lung cancer (NSCLC) with EGFR mutations; however, little is known about the efficacy and safety of this combination compared with that of standard therapy with EGFR- tyrosine kinase inhibitors alone. METHODS: We randomly assigned 345 patients with newly diagnosed metastatic NSCLC with EGFR mutations to gefitinib combined with carboplatin plus pemetrexed or gefitinib alone...
November 4, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31675272/lesion-level-response-dynamics-to-programmed-cell-death-protein-pd-1-blockade
#8
Juan C Osorio, Kathryn C Arbour, Dung T Le, Jennifer N Durham, Andrew J Plodkowski, Darragh F Halpenny, Michelle S Ginsberg, Peter Sawan, Joseph G Crompton, Helena A Yu, Azadeh Namakydoust, Barzin Y Nabet, Jamie E Chaft, Gregory J Riely, Hira Rizvi, Luis A Diaz, Matthew D Hellmann
PURPOSE: Response to programmed cell death protein 1 (PD-1) blockade is often conceptualized as resulting from reinvigoration of tumor-infiltrating lymphocytes. However, recruited antitumor immunity from the periphery may also be an important contributor to response. A detailed assessment of the response dynamics of individual metastasis could provide insight to the systemic and local features that mediate response and resistance to immunotherapy. MATERIALS AND METHODS: Patients with metastatic non-small-cell lung cancer (NSCLC) or mismatch repair deficiency (MMRD) carcinoma treated with PD-1 monotherapy were evaluated independently...
November 1, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31675253/finding-grace-in-grief
#9
Dylan E Graetz
No abstract text is available yet for this article.
November 1, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31675252/reply-to-a-katz
#10
N Lynn Henry, Fabrice Andre, Nofisat Ismaila, Mark R Somerfield, Vered Stearns
No abstract text is available yet for this article.
November 1, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31675251/bridging-the-data-free-zone-decision-making-for-older-adults-with-cancer
#11
EDITORIAL
Gabrielle B Rocque, Grant R Williams
No abstract text is available yet for this article.
November 1, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31675250/is-it-appropriate-to-use-the-result-of-an-unplanned-exploratory-nonstatistically-significant-subgroup-analysis-to-support-a-treatment-recommendation-in-an-asco-treatment-guideline
#12
LETTER
Artur Katz
No abstract text is available yet for this article.
November 1, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31675249/reply-to-h-mcleod-et-al
#13
Chana Weinstock, Laura L Fernandes, Marc Theoret, Shenghui Tang, Rajeshwari Sridhara, Julia A Beaver, Richard Pazdur
No abstract text is available yet for this article.
November 1, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31675248/assessment-of-adverse-events-and-their-ability-to-discriminate-response-to-anti-pd-1-pd-l1-antibody-immunotherapy
#14
LETTER
Howard L McLeod, Arshiya Mariam, Kimberly A Schveder, Daniel M Rotroff
No abstract text is available yet for this article.
November 1, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31675247/innovation-and-access-at-the-mercy-of-payment-policy-the-future-of-chimeric-antigen-receptor-therapies
#15
Christopher R Manz, David L Porter, Justin E Bekelman
No abstract text is available yet for this article.
November 1, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31675246/immortal-time-bias-question-in-the-association-between-toxicity-and-outcome-of-immune-checkpoint-inhibitors
#16
LETTER
Filippo G Dall'Olio, Vincenzo Di Nunno, Francesco Massari
No abstract text is available yet for this article.
November 1, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31664879/second-chances
#17
Christin B DeStefano
No abstract text is available yet for this article.
October 30, 2019: Journal of Clinical Oncology
https://read.qxmd.com/read/31657982/validation-of-the-dna-damage-immune-response-signature-in-patients-with-triple-negative-breast-cancer-from-the-swog-9313c-trial
#18
Priyanka Sharma, William E Barlow, Andrew K Godwin, Eileen E Parkes, Laura A Knight, Steven M Walker, Richard D Kennedy, Denis P Harkin, Gemma E Logan, Christopher J Steele, Shauna M Lambe, Sunil Badve, Yesim Gökmen-Polar, Harsh B Pathak, Kamilla Isakova, Hannah M Linden, Peggy Porter, Lajos Pusztai, Alastair M Thompson, Debu Tripathy, Gabriel N Hortobagyi, Daniel F Hayes
PURPOSE: To independently validate two biomarkers, a 44-gene DNA damage immune response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs), as prognostic markers in patients with triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin (A) and cyclophosphamide (C) in SWOG 9313. METHODS: Four hundred twenty-five centrally determined patient cases with TNBC from S9313 were identified. DDIR signature was performed on RNA isolated from formalin-fixed paraffin-embedded tumor tissue, and samples were classified as DDIR negative or positive using predefined cutoffs...
October 28, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31657981/improved-cns-control-of-childhood-acute-lymphoblastic-leukemia-without-cranial-irradiation-st-jude-total-therapy-study-16
#19
Sima Jeha, Deqing Pei, John Choi, Cheng Cheng, John T Sandlund, Elaine Coustan-Smith, Dario Campana, Hiroto Inaba, Jeffrey E Rubnitz, Raul C Ribeiro, Tanja A Gruber, Susana C Raimondi, Raja B Khan, Jun J Yang, Charles G Mullighan, James R Downing, William E Evans, Mary V Relling, Ching-Hon Pui
PURPOSE: Despite contemporary treatment, up to 10% of children with acute lymphoblastic leukemia still experience relapse. We evaluated whether a higher dosage of PEG-asparaginase and early intensification of triple intrathecal therapy would improve systemic and CNS control. PATIENTS AND METHODS: Between 2007 and 2017, 598 consecutive patients age 0 to 18 years received risk-directed chemotherapy without prophylactic cranial irradiation in the St Jude Total Therapy Study 16...
October 28, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31652094/randomized-trial-of-lenalidomide-versus-observation-in-smoldering-multiple-myeloma
#20
Sagar Lonial, Susanna Jacobus, Rafael Fonseca, Matthias Weiss, Shaji Kumar, Robert Z Orlowski, Jonathan L Kaufman, Abdulraheem M Yacoub, Francis K Buadi, Timothy O'Brien, Jeffrey V Matous, Daniel M Anderson, Robert V Emmons, Anuj Mahindra, Lynne I Wagner, Madhav V Dhodapkar, S Vincent Rajkumar
PURPOSE: Observation is the current standard of care for smoldering multiple myeloma. We hypothesized that early intervention with lenalidomide could delay progression to symptomatic multiple myeloma. METHODS: We conducted a randomized trial that assessed the efficacy of single-agent lenalidomide compared with observation in patients with intermediate- or high-risk smoldering multiple myeloma. Lenalidomide was administered orally at a dose of 25 mg on days 1 to 21 of a 28-day cycle...
October 25, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"